
Conference Coverage
Latest News

Q&A: Understanding Pneumococcal Disease Burden and Vaccine Opportunities

FDA Approves Sotyktu From Bristol Myers Squibb

De-escalating Treatment in HER2-Positive Breast Cancer: Doing More With Less

Optimizing Specialty Medication Access in Community Pharmacy: A Practical Workflow Approach

From Burnout to Balance: How Walgreens' Hybrid Model Is Addressing the Pharmacy

Shorts










Podcasts
Videos
Continuing Education
All News

Adjuvant PD-1/PD-L1 inhibitors improve disease-free and metastasis-free survival in patients with solid tumors but require careful patient selection.

Clinical trial insights link talquetamab resistance to GPRC5D loss in multiple myeloma; oncology pharmacy teams can spot escape and refine treatment.

When performed appropriately, medication reconciliations can reduce discrepancies from as high as 70% to as low as 15%.


COVID-19 infection may create lasting changes in the lung microenvironment—particularly through thymidine phosphorylase–driven pathways—that could increase the risk of lung cancer over time.

Anthony Blaszczyk, PhD, explains the intricacy of CGT manufacturing demands, best practices, and how USP is supporting developers.

Post-COVID access gaps fuel unsafe, unregulated botox and cosmetic injections; trained pharmacists can deliver regulated botulinum toxin injectables through voluntary specialization.

This decision builds upon the drug’s initial approval for adult patients and introduces a new therapeutic option for clinicians treating pediatric populations with rapid heart rate disturbances.

WHI data links radon exposure to higher ovarian cancer risk and deaths; learn how home testing may reduce cancer risk in high-radon areas.

Beyond memantine's approved use in Alzheimer disease, emerging evidence highlights a possible role for it in select epilepsy cases.

The indication is to reduce proteinuria in adults and children aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic symptoms.

Emerging therapeutic options represent a new age for treatment of high-risk non-muscle-invasive bladder cancer.

FDA fast track designation advances oral EP300/CBP inhibitor OPN-6602 for relapsed/refractory multiple myeloma, highighting novel hematology-oncology options and key pharmacist considerations.

Students should consider reaching out to their experiential education department to learn what opportunities may be available.

Real-world data show pharmacist-driven obesity care models may offer greater improvements in hemoglobin A1C and lipid parameters while supporting multidisciplinary, patient-centered care.

PCOS in female athletes often goes unrecognized due to atypical presentations, requiring careful differentiation, individualized management, and a multidisciplinary approach to protect both performance and long-term health.

As loneliness becomes a global health threat, pharmacies can take the social responsibility to combat isolation crisis and champion the community's health.

New data highlight the impact of pharmacist-driven continuous glucose monitoring services on hemoglobin A1C reduction, time in range, and medication adherence.

New evidence shows that human papillomavirus (HPV) 9-valent vaccine protection lasts up to 14 years. Learn why early vaccination and pharmacists can boost cancer prevention.

Educate patients to help avoid duplicate acetaminophen intake and prevent interactions, and know when to consult their physician.

Early immune signals can program longer-lasting lung-resident T cells—a potential breakthrough for influenza and COVID-19 vaccine design.

Peer review strengthens the quality, clarity, and credibility of manuscripts while providing professional and educational benefits to students in the process.

In AML, sialylated CD43 blocks immune clearance beyond CD47, revealing new leukemia targets to boost macrophage phagocytosis.




























